SCHEMBL5407550

SCHEMBL5407550

COc1ccc(CS[C@@H]2C[C@@H](CNCc3ccccc3)N(S(C)(=O)=O)C2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.43
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
ATM Q13315 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CXCR4 P61073 1/20 0.37
KDM1A O60341 1/20 0.37
MMP1 P03956 2/20 0.37
MMP3 P08254 2/20 0.37
MMP9 P14780 2/20 0.37
MMP13 P45452 2/20 0.37
MMP7 P09237 1/20 0.37
MMP2 P08253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407554 1.00 HTT (0.43) HTTMAPTPOLBMEN1KMT2A
SCHEMBL5406275 0.85 MMP1 (0.43) HTTMAPTPOLBLMNARECQL
SCHEMBL5401130 0.83 CASP3 (0.41) HTTMAPTLMNARECQLNPSR1
SCHEMBL5401128 0.83 CASP3 (0.41) HTTMAPTLMNARECQLNPSR1
SCHEMBL5405046 0.81 SIGMAR1 (0.38) KMT2AALDH1A1SMN1; SMN2MMP1MMP3
SCHEMBL5405049 0.81 SIGMAR1 (0.38) KMT2AALDH1A1SMN1; SMN2MMP1MMP3
SCHEMBL5409836 0.80 APLNR (0.37) MAPTALDH1A1SMN1; SMN2LMNARECQL
SCHEMBL5409843 0.80 APLNR (0.37) MAPTALDH1A1SMN1; SMN2LMNARECQL
SCHEMBL7140147 0.80 HTT (0.38) HTTMAPTPOLBKMT2AALDH1A1
SCHEMBL7140145 0.80 HTT (0.38) HTTMAPTPOLBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189756-B2 Pyrrolidine derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US disclosed
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia AEBI JOHANNES (CH) 2004-12-02 US disclosed
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed
US-20030199569-A1 Pyrrolidine derivatives AEBI JOHANNES (CH) 2003-10-23 US disclosed
US-20020040146-A1 Pyrrolidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199569-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 HTT 2507/4885MAPT 2593/4885POLB 1509/4885
US-20020040146-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 HTT 2507/4885MAPT 2593/4885POLB 1509/4885
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia MMP1, PEPD, MMP25 HTT 3375/4885MAPT 2934/4885POLB 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.